Overview
CTOR market data
Price History
CTOR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.34 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.44 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.49 – $2.84 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $53.6 · P/B 3.78.
Company news
Citius Oncology Expands LYMPHIR Launch Team Nationwide Ahead Of Full U.S. Deployment In AugustBenzinga · Jul 21, 2026, 1:19 PM
8-K filing — CITIUS ONCOLOGY, INC. (CTOR)SEC EDGAR · Jun 1, 2026, 8:30 PM
Citius Oncology Presents Phase 1 Clinical Data Of LYMPHIR In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies At American Society Of Clinical Oncology Annual MeetingBenzinga · Jun 1, 2026, 11:21 AM
Citius Oncology Highlighted Phase 1 Clinical Data Presented May 30, 2026, At The American Society Of Clinical Oncology Annual Meeting Evaluating Lymphir (Denileukin Diftitox-cxdl) In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic MalignanciesBenzinga · Jun 1, 2026, 11:07 AM